Reviewing the Potential of Psychedelics for the Treatment of PTSD
The International Journal of Neuropsychopharmacology March 12, 2020 Erwin Krediet, Tijmen Bostoen, Joost J. Breeksema et al. 262 citations
Posttraumatic stress disorder (PTSD) often remains chronic after psychotherapy, and few effective medications exist. A promising new approach involves psychedelic drugs. This review discusses four compound types: MDMA, ketamine, classical psychedelics (psilocybin, LSD), and cannabinoids. It describes each compound's therapeutic rationale, administration setting, and current evidence for treating PTSD. Each offers unique qualities, from rapidly targeting symptoms to facilitating psychotherapy. The review outlines questions for future research.